- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02443831
CARPALL: Immunotherapy With CD19/22 CAR T-cells for CD19+ Haematological Malignancies
Immunotherapy With CD19/22 CAR Redirected T-cells for High Risk, Relapsed Paediatric CD19+ and/or CD22+ Acute Lymphoblastic Leukaemia and Other Haematological Malignancies
Study Overview
Status
Conditions
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
London, United Kingdom
- Great Ormond Street Hospital
-
London, United Kingdom
- University College Hospital
-
Manchester, United Kingdom
- Manchester Royal Children's Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Children and young adults (age 24 years or younger) with high risk/relapsed CD19+ and / or CD22+ haematological malignancy:
A) Resistant disease (>5% blasts) at end of UKALL 2019 guidelines or equivalent induction B) ALL with persisting high level MRD at 2nd time point of frontline national protocol (currently MRD >10-4 at week 14 UKALL2019 guidelines or equivalent).
C) High risk infant ALL (age < 6 months at diagnosis with MLL gene rearrangement and either presenting white cell count > 300 x 109/L or poor steroid early response (i.e. circulating blast count >1x109/L following 7 day steroid pre-phase of induction as per national guidelines or equivalent) D) Intermediate risk infant ALL with MRD > 10-3 at end of induction following national guidelines or equivalent) E) High risk 1st relapse (as defined by updated IntreALL 2019 classification: bone marrow or combined relapse within 30 months of diagnosis OR any relapse within 18 months of diagnosis) F) Standard risk relapse in patients with high risk cytogenetics (defined as BCR-ABL, KMT2A rearrangement, near-haploidy (<30 chromosomes) and low hypodiploidy (30-39 chromosomes), iAMP21 and TCF3-HLF translocations).
G) Standard risk relapse with bone marrow minimal residual disease (MRD) > 10-3 at end of re-induction H) Any on therapy relapse in patients age 16-24 I) Any relapse of infant ALL J) ALL post ≥ 2nd relapse K) Any refractory relapse of ALL (defined as > 1% blasts by flow cytometry after a at least 1 cycle of standard chemotherapy) L) ALL with MRD >10-4 prior to planned stem cell transplant M) Any relapse of ALL eligible for stem cell transplant but no available HLA matched donor or other contraindication to transplant N) Any relapse of ALL after stem cell transplant O) Any relapse of Burkitt's or other CD19+ and/or CD22+lymphoma Note patients with isolated CNS relapse meeting one or more of the criteria above are eligible for the study
- Agreement to have a pregnancy test, use adequate contraception (if applicable)
- Written informed consent
Exclusion Criteria:
Exclusion Criteria for registration:
- Active Hepatitis B, C or HIV infection
- Oxygen saturation ≤ 90% on air
- Bilirubin > 3 x upper limit of normal
- Creatinine > 3 x upper limit of normal
- Women who are pregnant or breastfeeding
- Stem Cell Transplant patients only: active significant (overall Grade ≥ II, Seattle criteria) acute GVHD or moderate/ severe chronic GVHD (NIH consensus criteria) requiring systemic steroids.
- Inability to tolerate leucapheresis
- Karnofsky (age ≥ 10 years) or Lansky (age < 10) score ≤ 50%
- Pre-existing significant neurological disorder (other than CNS involvement of underlying haematological malignancy)
Exclusion criteria for CD19/22CAR T-cell infusion:
- Severe intercurrent infection at the time of scheduled CD19/22 CAR T-cell infusion
- Requirement for supplementary oxygen or active pulmonary infiltrates at the time of scheduled CD19/22 CAR T-cell infusion
- Allogeneic transplant recipients with active significant acute GVHD overall grade ≥II or moderate/severe chronic GVHD requiring systemic steroids at the time of scheduled CD19/22 CAR T-cell infusion. Note: Such patients will be excluded until the patient is GVHD free and off steroids
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: CD19/22 CAR T-cells
Patients meeting the eligibility criteria will have leukapheresis to isolate the blood immune cells used to manufacture the CD19/22CAR T-cells.
Patients will receive lymphodepletion with fludarabine and cyclophosphamide prior to infusion of the CD19/22CAR T-cells.
|
Patients will undergo an unstimulated leukapheresis to isolate the required immune cells to produce the CD19/22 CAR T-cells
Patients will receive lymphodepleting chemotherapy with iv fludarabine 30 mg/m2 on days -7 to -3 prior to CD19/22CAR T-cell infusion.
Patients will receive lymphodepleting chemotherapy with iv cyclophosphamide 0.5 g/m2 on days -4 to -2 prior to CD19/22CAR T-cell infusion.
A single dose of 1 x 10^6/kg CD19/22CAR transduced T-cells will be given as an intravenous injection through a Hickman line or PICC line(peripherally inserted central catheter) on day 0.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Toxicity evaluation following CD19/22CAR T-cell infusion
Time Frame: 1 month
|
The incidence of grade 3-5 toxicity occurring within 60 days of CD19/22CAR T-cell infusion.
In particular, the incidence of Severe Cytokine Release Syndrome and Grade 3-5 neurotoxicity occurring within 30 days of CD19/22CAR T-cell infusion.
|
1 month
|
Molecular remission
Time Frame: 1 month
|
Efficacy will be assessed by determining Minimal Residual Disease in the bone marrow aspirate using immunoglobulin heavy chain (IgH) quantitative polymerase chain reaction (qPCR) and/or Next Generation Sequencing in all patients.
The proportion of patients achieving molecular remission at 1 month post CD19/22CAR T-cell infusion will be determined.
|
1 month
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Long term molecular remission
Time Frame: 2 years
|
Number of patients in molecular remission without further therapy at 2 years
|
2 years
|
Frequency of circulating CD19/22 CAR T-cells
Time Frame: 2 years
|
Persistence and frequency of circulating CD19/22CAR T-cells in the peripheral blood by flow cytometry and qPCR analyses.
|
2 years
|
Incidence of hypogammaglobulinaemia
Time Frame: 2 years
|
Incidence and duration of hypogammaglobulinaemia
|
2 years
|
Relapse rate
Time Frame: 10 years
|
Relapse rate monitored during interventional phase and long term follow up for a total of10 years post cell infusion.
Number of patients who relapsed can be summarized as a percentage or rate(for all patients registered to the trial, and also only for those who received the cell infusion).
|
10 years
|
Overall Survival
Time Frame: 10 years
|
Overall survival is monitored during interventional phase and long term follow up for 10 years post-CD19/22 CAR T-cell infusion.
Number of patients alive can be summarized as a percentage (for all patients registered to the trial, and also only for those who received the cell infusion).
|
10 years
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Persis Amrolia, UCL Institute of Child Health
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Virus Diseases
- Infections
- Immune System Diseases
- Neoplasms by Histologic Type
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Lymphoma, Non-Hodgkin
- Neoplasms by Site
- Hematologic Diseases
- DNA Virus Infections
- Tumor Virus Infections
- Epstein-Barr Virus Infections
- Herpesviridae Infections
- Lymphoma
- Lymphoma, B-Cell
- Neoplasms
- Hematologic Neoplasms
- Leukemia
- Burkitt Lymphoma
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Leukemia, Lymphoid
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antirheumatic Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Cyclophosphamide
- Fludarabine
Other Study ID Numbers
- UCL 14/0529
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Burkitt Lymphoma
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedRecurrent Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia | Recurrent Burkitt Lymphoma | AIDS-Related Burkitt Lymphoma | Atypical Burkitt/Burkitt-Like Lymphoma | High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements | High Grade B-Cell Lymphoma With MYC, BCL2... and other conditionsUnited States
-
Northwestern UniversityNational Cancer Institute (NCI); Millennium Pharmaceuticals, Inc.Active, not recruitingDiffuse Large B-Cell Lymphoma | Plasmablastic Lymphoma | B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma | Adult Burkitt Lymphoma | MYC Gene MutationUnited States
-
Dana-Farber Cancer InstituteBeth Israel Deaconess Medical Center; Brigham and Women's HospitalTerminatedBurkitt Lymphoma | Non-Hodgkins Lymphoma | Atypical Burkitt LymphomaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedChildhood Burkitt Lymphoma | Childhood Lymphoblastic LymphomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingRecurrent Adult Lymphoblastic Lymphoma | Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements | Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements | Recurrent Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia | Recurrent... and other conditionsUnited States
-
PETHEMA FoundationGrupo Español de Linfomas y Transplante Autólogo de Médula ÓseaRecruitingMature B-Cell Leukemia Burkitt Type | Burkitt Lymphoma (BL) | Unclassifiable Lymphoma Between DCBL and BLSpain
-
Hospices Civils de LyonThe Lymphoma Academic Research OrganisationRecruitingMantle Cell Lymphoma (MCL) | Follicular Lymphoma (FL) | Diffuse Large B Lymphoma (DLBCL) | Marginal Zone Lymphoma (MZL) | T-cell Lymphoma (T-NHL) | Hodgkin's Lymphoma (HL) | Burkitt Lymphoma (BL))France
-
National Cancer Institute (NCI)CompletedRecurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell LymphomaUnited States
-
Beth ChristianGenentech, Inc.; CelgeneActive, not recruitingRecurrent Marginal Zone Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent Burkitt Lymphoma | Recurrent Follicular Lymphoma | Refractory Follicular Lymphoma | Refractory Burkitt Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular Lymphoma and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Mantle Cell LymphomaUnited States
Clinical Trials on Leukapheresis
-
University Hospital, Basel, SwitzerlandCompleted
-
Herbert Irving Comprehensive Cancer CenterNational Cancer Institute (NCI)Unknown
-
University of California, San FranciscoRecruiting
-
M.D. Anderson Cancer CenterRecruitingLymphomas | B-cell LymphomasUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedDiamond Blackfan AnemiaUnited States
-
Polyphor Ltd.CompletedMyeloproliferative Disorders | Adult Acute Lymphoblastic Leukemia in Remission | Chronic Lymphocytic Leukemia (CLL) | Myelodysplastic Syndrome (MDS) | Acute Myeloid Leukemia in Remission | Chronic Myelogenous Leukemia (CML) | Multiple Myeloma (MM) | Non-Hodgkin's Lymphoma (NHL) or Hodgkin's Disease...United States
-
Serhat Gumrukcu, MD PhDThe Scripps Research InstituteSuspended
-
Mayo ClinicNational Cancer Institute (NCI)Completed
-
Washington University School of MedicineBioLineRx, Ltd.CompletedMultiple Myeloma | Hodgkin Disease | Non-Hodgkin's Lymphoma | Acute Lymphoblastic Leukemia | Non-Hodgkin Lymphoma | Myelodysplastic Syndrome | Acute Myelogenous Leukemia | Chronic Myelogenous Leukemia | Myeloproliferative Neoplasm | Hodgkin's Disease | Hodgkins DiseaseUnited States
-
Memorial Sloan Kettering Cancer CenterTerminated